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Introduction
Global prevalence of hepatitis C is about 3% and 
approximately 170 million people in worldwide are 
infected with the virus. Hepatitis C virus has a positive 
linear RNA and this virus classified in the family of 
Flaviviridae and the genus of Hepacivirus. HCV virion 
is about 50 to 60 nm and has 9.4 Kb length which is 
responsible to code about 3010 amino acids (Keyvani et 
al., 2012). The prevalence of HCV in America, Canada 
and Northern Europe is less than 1% and in Thailand, 
Malaysia and India is from 2.1 to 1.4%. This prevalence 
in Ukraine is 9.2% and in North and sub-Saharan Africa 
and Arabic countries including Egypt is14.5% (Zekri et 
al., 2012). HCV infection can be seen all over the world, 
but in the Eastern Mediterranean Region and Africa have 
the highest rates of incidence. 
HCV is divided into six major genotypes and more 
1Department of Medical Microbiology, 2Department of Medical Virology, Kerman University of Medical Sciences, Kerman, 
2Department of Gastroentrology, Iran University of Medical Sciences, Tehran, Iran  *For correspondence: hamid2008kmu@gmail.com
Abstract
 Polymorphisms in the region of the interleukin IL-28 gene on chromosome 19 have been related with 
clearance of hepatitis C virus (HCV), a major human pathogen responsible for chronic hepatitis, cirrhosis and 
hepatocellular carcinoma. About 3% of the world’s population is infected with HCV. The long-term response to 
therapy is influenced by many host and viral factors, and recent evidence has indicated that some host genetic 
polymorphisms related to IL-28 are the most powerful predictors of virological response in patients with HCV. 
This study assessed frequency of the IL-28 polymorphism (rs8099917) in 50 patients (39 men and 11 women ) 
with chronic hepatitis C using ZNA probe real time PCR new method . All patients were tested for genotype of 
HCV and the HCV viral load. In parallel, the levels of SGOT, SGPT and ALK enzymes were assessed. Treatment 
using Peg-interferon alpha with ribavirin was conducted for patients and subsequently samples were collected 
to detect any change in viral load or liver enzyme rates. The overall frequency of the TT allele is 74%, TG allele 
20% and GG allele 6% and the percent of patients who had T allele was 84%. Clear reduction in viral load and 
liver enzymes was reported in patients with the T allele. Especially for genotype 1 which is relatively resistant 
to treatment, these alleles may have a role in this decline. In conclusion, we showed that IL-28 polymorphism 
rs8099917 strongly predicts virological response in HCV infection and that real-time PCR with Zip nucleic 
acid probes is a sensitive, specific and rapid detection method for detection of SNPs which will be essential for 
monitoring patients undergoing antiviral therapy. 
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than 80 subtypes. HCV genotypes 1 and 4 are common 
in Western countries and type 1 is dominant in North 
America, West Europe and Japan (Al-Kubaisy et al., 
2014). Genotype 1 has the minimum response to treatment 
but genotype 2 has the best action in treatment and type 
3 has the highest rate of spontaneous resolution. While 
getting chronic HCV is common in genotype 4. Generally, 
types 1 and 3 are in Europe and America and type 3 is 
prevalent in Africa (Petruzziello et al., 2014). In Iran, 
the highest prevalence 1.5% and the lowest 0.2% has 
been reported but still now HCV is the most important 
reason of hemophilia, thalassemia and renal failure and 
hemodialysis (Jamalidoust et al., 2014). 
Sustain virological response (SVR) is known as a 
follow up of HCV 6 months after treatment. This response 
is varied between patients. Some factors such as genotype 
2 and 3, low-level in viral load, absence of cirrhosis, 
female sex, and the age less than 40 years increase the 
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response to treatment. In addition, the study of the human 
genome has shown that the IL28B polymorphism is 
involved on SVR response (Lazarus et al., 2014; Yoshida 
et al., 2014a). The IL28B gene is encoding interferon λ3. 
This IFN with interferon λ1 (coded by IL29) and interferon 
λ (coded by IL28A) make interferon λ family. 
Genes of IL28A, B and IL29 are located on chromosome 
19 and in gene of IFN λ3 some polymorphisms such 
as rs8099917, rs12979860, rs4803219, rs10853727, 
rs8109886, rs4803223, rs12980602 and rs12980275 have 
been reported. The most important polymorphisms in 
IL28B are rs12979860 and rs8099917 (Riva et al., 2014; 
Rosso et al., 2014). Single nucleotide polymorphisms 
(SNP) rs12979860 is 3 kb upstream of the IL28B gene 
and SNP rs8099917 is located 8 kb upstream of the 
IL28B gene (Labie and Gilgenkrantz, 2010) (Figure 1). 
For treatment of hepatitis C, newly peg-interferon plus 
Ribavirin is an antiviral drug for the individual based on 
genotypes being used. Although, these materials have side 
effects such as: flu-like symptoms, fever and muscle aches 
for interferon alpha and destruction of red blood cells for 
Ribavirin have been reported (Callau Monje et al., 2014; 
Riva et al., 2014). 
Many methods were developed to detect SNPs, such 
as direct polymerase chain reaction (PCR) sequencing , 
restriction fragment length polymorphism (PCR-RFLP), 
High resolution melting curve Analyses(HRM), matrix-
assisted laser desorption/ionization time of fight-mass 
spectrometry (MALDI TOF MS) with their respective 
advantages and disadvantages (Moosavy et al., 2011). 
Sequencing remains the best approach to the identification 
of new mutations. However, it cannot detect total 
mutations in less than 25% of total Gene population and is 
not appropriate for large-scale use in large cohort studies 
or clinical laboratories because of its labor intensive and 
time consuming (Aghasadeghi et al., 2011). MALDI 
TOF MS are capable to detect variants, but more strict 
experiment conditions and equipment’s are required. PCR-
RFLP could only detect mutations in a high proportion 
and is also labor intensive and time consuming (Aberle et 
al., 2001). Monitoring of gene mutations and SNPs will 
play an important role in assessing treatment. Prolonged 
treatment with antiviral agents can lead to the emergence 
of drug-resistant virus (Chen et al., 2010). 
Zip nucleic acids (ZNAs) are oligonucleotides 
conjugated with cationic spermine units which increase 
affinity for their target by decreasing electrostatic repulsion 
between negatively charged anionic single strand Nucleic 
Acids to improve hybridization, thus enhancing and 
accelerating target recognition (Noir et al., 2008). The 
possibility of modulating the global charge of the ZNA 
oligonucleotide-oligocation conjugates by the number of 
cationic spermine moieties attached to the Nucleic Acid 
oligomer, is a key to predict melting temperature of ZNA-
DNA/ZNA-RNA hybrids easily. Tm increases linearly 
with the length of the oligocation (Afshar and Mollaie, 
2012; Alvandi and Koohdani, 2014). ZNAs were shown 
to enable specific and sensitive reactions when used as 
primers for PCR and Reverse Transcription. Moreover 
ZNA probes provide broad flexibility in assay design and 
represent an effective alternative to Minor Groove Binder 
(MGB) and Locked Nucleic Acid (LNA) containing 
oligonucleotides (Voirin et al., 2007). 
With the study of the human genome, some genes and 
polymorphisms have been found which are important in 
HCV treatment. Scientists ensure that polymorphisms 
in IL28B gene are directly linked with spontaneous 
clearance of HCV and the result of treatments (Bibert 
et al., 2013). Thus, detection of mutants or SNPs to 
treatment is necessary to prevent disease progression and 
malignancy and recommended for rapid identification and 
sensitive treatment monitoring (De et al., 2014). In this 
study described a sensitive method for detection of IL-
28 polymorphism (rs8099917) by Real-time fluorescent 
quantitative PCR using ZNA-probes in Chronic HCV 
patients who had been long-term Antiviral therapy in 
Kerman, southeast of Iran. So far no study has been done 
in this area with same method. This method can be used 
to detect rs8099917 and other SNPs in IL-28 in a single 
multiplex reaction simultaneously.
Materials and Methods
Patients
In retrospective study, fifty patients (39 cases were 
male (78%) and 11 cases were female (22%) and 23 of 
males (58.9%) and 3 of females (27.2%) had genotype 1. 
On the other hand, 16 of men (41.1%) and 8 of women 
(72.8%) had HCV genotype 3. mean age=42 years, range 
38-55 years) who were diagnosed as Chronic Hepatitis C 
infection from Jan 2012 to Sep 2014 in our Laboratory 
(Virology Laboratory of the Besat Specialist Clinic, 
Kerman, IRAN) following the guidelines of prevention 
and treatment of chronic hepatitis C were enrolled in 
this study. The decision to treat is primarily based on the 
combination of three criteria: a) serum HCV RNA levels, 
b) serum alanine amino transferase (ALT) levels and c) 
histological grade and stage of the underlying liver disease. 
Exclusion criteria included a coexisting severe illness, 
organ or bone marrow transplantation, recent treatment 
with systemic corticosteroids, immunosuppressant’s or 
chemotherapeutic agents, liver disease not due to hepatitis 
C, and seropositivity for human immunodeficiency virus 
(HIV) or hepatitis B(HBV) or hepatitis D virus.
Serological tests
The blood from the patients with chronic hepatitis 
C was assayed for alanine transaminase at our clinical 
laboratory using an automated analyzer. HBsAg and 
HBeAg as well as Anti-HCV and Anti-HIV were 
determined using commercial radioimmunoassay kits 
(Abbott Laboratories, Chicago, IL). Hepatitis D antigen 
was detected using enzyme immunoassay kits (Abbott 
Laboratories, Chicago, IL). 
HCV RNA level and Genotyping
Five ml of peripheral blood were collected from 
each patient into EDTA-containing vacutainer tubes. 
Plasma was separated and stored at -70°C. HCV RNA 
was extracted from 200 μL of plasma with High Pure 
Viral Nucleic Acid kit (Roche Diagnostics GmbH, 
Mannheim, Germany). Plasma HCV-RNA levels were 
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quantified via quantitative Real-time polymerase chain 
reaction with a commercial detection kit (artus HCV kit, 
Qiagen, Germany). The Real-time PCR had a lower limit 
of 10 copies/mL. HCV genotyping was performed with 
a commercial HCV genotyping detection kit (Inter Lab 
Service , Russia). 
Detection IL28 polymorphism rs 8099917
Detection of rs 8099917 was done with specific 
primers and probes from position 301 of the IL-28B 
region that were design by Dr H.R.Mollaie Using Beacon 
designer software that were shown in Table 1 (Version 8 
Primer, Biosoft, USA). Primers and probes synthesized 
by Metabion company (metabion international AG, 
Germany). five µl of DNA sample that was extracted 
from PBMNs , combined with 15 µl reaction mixture of 
fermentas TaqMan Master mix (Thermo fisher Scientific, 
USA) contain primers and probe were subjected to 
Real-time PCR. The condition for the ZNA mediated 
probe assay was initially 15 min with hot start Taq DNA 
polymerase at 95°C followed by 40 cycles at 95°C for 5 
sec and 60°C for 20 sec. Of each cycle at the extension 
step, the fluorescent signals of Probe rs 8099917 were 
measured at Green channel for T allel, Yellow for G allel. 
Quantitative determination of the amplified products 
was done with the Rotor Gene 6000 (Corbett Research, 
Australia). 
Statistical analyses
Chi square and Fisher’s exact Tests were used to 
analyze the data obtained by SPSS 11.5 software (SPSS 
Inc, Chicago; USA). The differences or association with 
p<0.05 were considered statistically significant.
Results 
In our research, 50 patients with chronic hepatitis 
C were studied before and after treatment by Peg-
interferon alpha with Ribavirin and the frequency of 
allele polymorphism rs8099917 for interleukin 28 were 
investigated. The result revealed that the allele frequency 
of rs8099917 polymorphism is 74% for TT genotype 
(37 patients), 20% for TG allele (10 patients) and 6% 
for GG allele (3 patients). Out of the 50 patients, 39 
cases were male (78%) and 11 cases were female (22%) 
and 23 of males (58.9%) and 3 of females (27.2%) had 
genotype 1. On the other hand, 16 of men (41.1%) and 
8 of women (72.8%) had HCV genotype 3.Our result 
shows that, from the total 37 patients with alleles TT, 16 
cases (43.3%) had genotype 1 and 21 samples (56.7%) 
were HCV genotype 3. From total 10 patients with allele 
TG, 8 samples (80%) had genotype 1 and 2 cases (20%) 
were HCV genotype 3. From 3 persons with allele GG, 
2 patients (66.6%) with genotype 1 and 1 case (33.3%) 
was HCV genotype 3.The viral load, AST, ALT and ALK 
levels in three alleles (GG, TT, and GT) were studied 
before and after treatment. The mean of viral load level 
in TT and GT is decreasing from (6.39±0.4)×106 copies/
ml to (44.17±0.2)×102 copies/ml, (7.49±0.7)×107 copies/
ml to 102.74±0.363 copies/ml respectively. The rate of 
liver enzymes has a similar reduction (Figure 2). As it 
is reported, for patients with TT allele, the mean of AST 
enzyme was 323±58.9 before treatment and after treatment 
became 70.87±7.6. For patients with TT allele, the mean 
of ALT enzyme was 335. 68±65.18 before and 73.7±7.6 
after treatment. For ALK enzyme in TT allele, the mean 
of 668±20 before and 153.31±78.83 after treatment were 
reported. As it is shown, the rate of AST, ALT and ALK 
enzymes is dropping after treatment in HCV genotype 
1 patients with GT allele. Viral load levels and liver 
enzymes were significantly reduced in TT and GT allele 
and since genotype 1 is relatively resistant to treatment, 
these alleles may have a role in this decline (Figure 3). 
The mean of viral load level in TT and GT is decreasing. 
The rate of liver enzymes has a similar reduction. As it 
is reported, for patients with TT allele, the mean of AST 
enzyme was 325±44 before treatment and after treatment 
became 63±5. For patients with TT allele, the mean of ALT 
enzyme was 248±35 before and 61±30 after treatment. 
For ALK enzyme in TT allele, the mean of 680±54 before 
and 136±13 after treatment were reported. As it is shown, 
the rate of AST, ALT and ALK enzymes is dropping after 
treatment in HCV genotype 3 patients with GT allele. Viral 
load and liver enzymes were significantly decreased in 
patients with TT and GT allele but because there is only 
one sample with GG allele, statistical comparison is not 
available. In our survey, the viral load of HCV genotype 
3 was studied some weeks before and after treatment as. 
In Figure 4, the frequency mean of HCV viral load in 
different weeks during drug therapy were shown. The viral 
load in patients with HCV genotype 1 was evaluated to 
compare changes in weeks before and during treatment. In 
11 patients the mean of AST level 12 weeks before drug 
therapy was 197±58, and after treatment became 62±8 
and also 7 samples were 275± 99 and 60±15, 13 weeks 
before and after treatment. Other changes in AST enzyme 
were clarified for 14, 15 and 21 weeks before and after 
treatment. The rate of ALT enzyme in patients with HCV 
genotype 3 studied some weeks during treatment. In 11 
patients the mean of ALT rate 12 weeks after drug therapy 
was 209±65 and also 7 samples were shown 298±55. Other 
changes in ALT enzyme were clarified for 14, 15 and 21 
weeks after treatment.In our survey, the ALK enzyme in 
patients with HCV genotype 3 was studied some weeks 
during treatment. In 11 patients the mean of ALK 12 
weeks after drug therapy was 718±13, and 21 weeks after 
Table 1. Sequence Primer and Probe for Detection rs 8099917 Polymorphism
Name Sequence Tm
Forward primer GTTCCTCCTTTTGTTTTCC 49.6
Reverse Primer GTCATTTGCCTTTACTATCC 49.7
T allel Probe FAM- TCTGTGAGCAATTTCACCCAAATT- BHQ1 58.6
G allel Probe  HEX-TCTGTGAGCAATGTCACCCAAATT- BHQ1 60.2
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treatment became 122±13 and also 7 samples were 580±12 
and 130±10, 13 weeks after treatment. Other changes in 
ALK rates were clarified for 14, 15 and 21 weeks before 
and after treatment.The AST enzyme rate in patients was 
analyzed to compare changes in weeks during treatment. 
In 6 cases the mean of AST was reported 22 weeks after 
treatment was 294±83 and after drug therapy was 73±12. 
Other patients who had HCV Genotype 1 were studied 
in 12-26 weeks after treatment and strong reduction in 
their AST enzymes were published. The ALT enzyme of 
patients with HCV genotype 1 was shown some weeks 
after treatment. In 6 patients the mean of ALT rate 22 
weeks after drug therapy was 301±45 and 26 weeks after 
treatment became 74±6. In 12-26 weeks after treatment 
in patients who had HCV Genotype 1, sharp reductions 
in their ALT enzymes were published.
Discussion
To date, many assays have been used for detection of 
IL-28 mutants in patients with hepatitis C. Differences 
in sensitivity, specificity, cost, and time required, exist in 
these methods. Real-time PCR is able to quantitatively 
detect a small portion of mutants in populations and ZNA 
probe detection method is a newly developed method for 
detection of low abundant mutants in the background of 
wild-types. So we used these methods and we could detect 
single mutation about IL-28. In our study most of drug 
resistance cases were in men. Sequence analysis, on the 
other hand, has already proven to be a useful technique 
for mutation detection, however, it takes more time and 
cannot be used everywhere and also cannot detect any 
mixtures of variants, but sequencing results of this study 
were same to our method which used in this study. Using 
ZNA probe method is quick and inexpensive comparing 
to other probe methods for detection of SNP mutation; and 
ZNA probe method is more trustable than other methods. 
The results obtained with both methods were completely 
concordant in all samples. ZNA was able to detect as low 
as 10 copies/mL of SNP, while other method only detected 
1000 copies/mL of Mutants. In addition, the cost of ZNA 
is slightly lower and is much more rapid so it requires 
less manual work than PCR-RFLP. The total assay time 
for ZNA real-time PCR was 1.5 hours, respectively. 
Another advantage of the real-time PCR method is it 
is able to calculate the ratio of mutants to total virus in 
samples. This will be useful in clinical studies on the 
dynamics of resistant mutants during lamivudine therapy 
(Li et al., 2012). The presence of IL-28 polymorphisms 
like rs12980275, rs8099917 and rs12979860 can make 
big effects on instant treatment responses against HCV 
infection. According to the given role for interferon 
lambda, it is mentioned that the polymorphisms of 
this cytokine family can be associated with a variety 
of physiological conditions and diseases (Melis et al., 
2011). Several investigators on polymorphisms and their 
importance in hepatitis C and response to treatment of this 
disease have examined and the association between the 
SNP of IL28B and the response of virus in HCV positive 
patients have noted. Unfortunately, the treatment of this 
group of patients is very costly and time consuming with 
a lot of side effects. So this project was done on HCV 
positive patients in Kerman, southeast of IRAN, to get a 
valuable resource for further study and having got a good 
plan for host based genetic basis. According to the role 
Figure 2. Relative Differentiation between HCV Viral 
Load before and after Treatment (Mean±SD). (Viral 
Load B) Viral Load before treatment in HCV genotype 1, Viral 
load A) Viral Load after treatment in HCV genotype 1,Viral Load 
C) Viral Load before treatment in HCV genotype 3,viral Load 
D) Viral Load  after treatment in HCV genotype 3)
Figure 3. Differentiation between Liver Function Tests 
(Mean±SD) before and After Treatment in Patients 
with HCV Genotype3 with Different Allel for rs 
8099917 (A) After treatment; B) Before treatment)
Figure 4. Reduce HCV Viral Load in Weeks During 
Treatment
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of IL28B polymorphisms in hepatitis C treatment, we 
examined the frequency of genotypes 1and3 for rs8099917 
gene in HCV patients who had received PEG-IFN- α 
and Ribavirin therapy. It has been proved that variant 
IL28 is important in HCV infection and T allele is called 
responder allele and G allele is known no responder 
allele. These can be used as prognostic factors in patients 
with hepatitis C virus (Fischer et al., 2013; Harada et 
al., 2014). In a study to examine allele polymorphism 
rs8099917 for interleukin 28 and showed that the allele 
TT frequency has a significant positive relationship with 
SVR and suggests that host genetics may be useful for 
prediction of viral response (Aparicio et al., 2010). In 2009 
in Japan, 314 patients evaluated and TT allele frequency 
64% reported and showed that TT has more role than 
GG in viral response in patients. In a same research done 
by Ravesh in Switzerland in 2010 on whites 68% for TT 
allele have mentioned and said that GG allele has a role 
for chronic HCV. Our data revealed that the frequency of 
TT allele is 74%, TG allele 20% and GG allele is 6% and 
also in our study the percent of patients who had T allele 
is 84% of cases and G allele is 16% of cases (Seaberg et 
al., 2014; Tanaka et al., 2014). Most of the cited studies 
are explaining that the T allele is dominant in their studies 
which are similar to our data that shows 74% in T allele 
frequency (Yoshida et al., 2014b; Zhang et al., 2014). 
Different variants of IL-28 are strongly predictive factors 
for sustained viral response, particularly in patients with 
genotype 1 virus and T allele for rs12979860 is a good 
reason for viral load reduction after treatment (Bibert et al., 
2013). In Iran a study was done on 48 patients with HCV 
type 1 in Tehran that CC genotype is more relevant than 
TT in rs12979860 (IL28) for making better SVR which 
is different comparing with our result. Another survey 
was done in Iran and 118 patients were studied for IL28 
polymorphism rs8099917 and revealed that TT allele is 
dominant in Iranian patients. The analysis of our data 
shows similar result (Hashemi et al., 2012). In our survey 
the viral loads and the rate of liver enzymes evaluated 
before and after treatment based on different alleles of 
rs8099917 in patients with genotype 1. The result shows 
a significant decrease in viral loads and the rate of liver 
enzymes in patients with TT allele. Since it can be difficult 
to treat HCV genotype 1, TT allele probability can reduce 
the viral load and the enzymes. In summary, our findings 
suggest that SNP rs8099917 of IL28B are useful baseline 
predictors for virological response in patients infected 
with genotype 1 and 3 HCV when treated with Peg-IFN 
plus ribavirin.
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